Supplementary Figure S1 from MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model
Year: 2023
Type: supplementary-materials
Abstract: A. we treated a panel of breast cancer cells MDA-MB-468, SUM190, KPL-4, and MDA-IBC-3 with different concentrations of selumetinib and assessed cell viability by WST-1 assay 72 hours later. We observed that in MDA-MB-468, SUM190, KPL-4, and MDA-IBC-3 cells, the 50% inhibitory concentration (IC50) was above 20 µM. B. MDA-MB-231 and SUM149 cells were treated with selumetinib for 72 hours, and FACS analysis was performed to determine cell cycle distribution using propidium iodide.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362526828